MindWalk Holdings Corp. (NASDAQ:HYFT) Receives $5.00 Consensus Price Target from Analysts

MindWalk Holdings Corp. (NASDAQ:HYFT) has been given a consensus recommendation of “Hold” by the five analysts that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $5.00.

A number of research firms recently weighed in on HYFT. Wall Street Zen raised MindWalk from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. HC Wainwright reiterated a “buy” rating on shares of MindWalk in a research report on Monday, July 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of MindWalk in a report on Wednesday, July 15th. Finally, Zacks Research lowered shares of MindWalk from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 28th.

Institutional Trading of MindWalk

A hedge fund recently bought a new stake in MindWalk stock. BlackRock Inc. bought a new stake in MindWalk Holdings Corp. (NASDAQ:HYFT) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 154,411 shares of the company’s stock, valued at approximately $244,000. BlackRock Inc. owned 0.33% of MindWalk as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 6.70% of the company’s stock.

MindWalk Trading Up 15.9%

Shares of NASDAQ:HYFT opened at $1.31 on Friday. The company has a market cap of $61.19 million, a P/E ratio of -5.04 and a beta of 0.82. The stock’s 50-day moving average is $1.36 and its 200-day moving average is $1.36. MindWalk has a 52-week low of $0.99 and a 52-week high of $2.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.72 and a current ratio of 1.84.

MindWalk (NASDAQ:HYFT) last posted its quarterly earnings data on Monday, September 14th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.04). MindWalk had a negative return on equity of 133.26% and a negative net margin of 105.11%.The business had revenue of $2.75 million for the quarter, compared to analyst estimates of $3.25 million. Equities research analysts predict that MindWalk will post -0.21 earnings per share for the current year.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.